TERN-201 NASH clinical trial : Terns reports positive results for phase 1 study
TERN-201 NASH clinical trial : Terns Pharmaceuticals said that an ongoing phase 1 trial of its semicarbazide-sensitive amine oxidase (SSAO) inhibitor TERN-201 in non-alcoholic steatohepatitis (NASH) has yielded positive results. According to the US biopharma company, the early-stage NASH clinical study showed that a single oral dose of TERN-201 delivered a sustained, near-complete suppression of […]
Viking Therapeutics has initiated the VOYAGE study, a phase 2b clinical trial of its liver-selective thyroid hormone receptor beta agonist VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The California-based biopharma company said that clinical trial sites have been opened for enrolling patients after it got clearance of investigational new drug (IND) application for the NASH […]
Continue reading …
Business News Today
- Delivery Hero to acquire Latin American business of Glovo in €230m deal
- Amazon India opens two new fulfilment centres in Hyderabad
- Volansi bags $50m in Series B round for middle-mile drone delivery services
- British clothing retailer Next to form JV with Victoria’s Secret UK
- Cocomels launches new Sugar Free Coconut Milk Caramels
- Verizon to acquire US prepaid wireless provider Tracfone Wireless from America Movil
- NVIDIA to acquire British chip designer Arm from SoftBank for $40bn
- Neptune Energy gets NPD nod for drilling 6406/12-G-1 H well in PL 586
- Seattle Genetics signs $4.4bn worth oncology deals with Merck
- Gilead acquisition of Immunomedics : Pharma giant to gain access to breast cancer drug Trodelvy
